» Articles » PMID: 33010175

Strict Conformational Demands of RNA Cleavage in Bulge-loops Created by Peptidyl-oligonucleotide Conjugates

Overview
Specialty Biochemistry
Date 2020 Oct 3
PMID 33010175
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Potent knockdown of pathogenic RNA in vivo is an urgent health need unmet by both small-molecule and biologic drugs. 'Smart' supramolecular assembly of catalysts offers precise recognition and potent destruction of targeted RNA, hitherto not found in nature. Peptidyl-oligonucleotide ribonucleases are here chemically engineered to create and attack bulge-loop regions upon hybridization to target RNA. Catalytic peptide was incorporated either via a centrally modified nucleotide (Type 1) or through an abasic sugar residue (Type 2) within the RNA-recognition motif to reveal striking differences in biological performance and strict structural demands of ribonuclease activity. None of the Type 1 conjugates were catalytically active, whereas all Type 2 conjugates cleaved RNA target in a sequence-specific manner, with up to 90% cleavage from 5-nt bulge-loops (BC5-α and BC5L-β anomers) through multiple cuts, including in folds nearby. Molecular dynamics simulations provided structural explanation of accessibility of the RNA cleavage sites to the peptide with adoption of an 'in-line' attack conformation for catalysis. Hybridization assays and enzymatic probing with RNases illuminated how RNA binding specificity and dissociation after cleavage can be balanced to permit turnover of the catalytic reaction. This is an essential requirement for inactivation of multiple copies of disease-associated RNA and therapeutic efficacy.

Citing Articles

Bulge-Forming miRNases Cleave Oncogenic miRNAs at the Central Loop Region in a Sequence-Specific Manner.

Patutina O, Chiglintseva D, Amirloo B, Clarke D, Gaponova S, Vlassov V Int J Mol Sci. 2022; 23(12).

PMID: 35743015 PMC: 9224474. DOI: 10.3390/ijms23126562.


Influence of sequence variation on the RNA cleavage activity of Zn-dimethyl-dppz-PNA-based artificial enzymes.

Luige O, Karale K, Bose P, Bollmark M, Tedebark U, Murtola M RSC Adv. 2022; 12(9):5398-5406.

PMID: 35425588 PMC: 8981518. DOI: 10.1039/d1ra08319h.


Innovative developments and emerging technologies in RNA therapeutics.

Halloy F, Biscans A, Bujold K, Debacker A, Hill A, Lacroix A RNA Biol. 2022; 19(1):313-332.

PMID: 35188077 PMC: 8865321. DOI: 10.1080/15476286.2022.2027150.


"Bind, cleave and leave": multiple turnover catalysis of RNA cleavage by bulge-loop inducing supramolecular conjugates.

Amirloo B, Staroseletz Y, Yousaf S, Clarke D, Brown T, Aojula H Nucleic Acids Res. 2021; 50(2):651-673.

PMID: 34967410 PMC: 8789077. DOI: 10.1093/nar/gkab1273.


Site-Selective Artificial Ribonucleases: Renaissance of Oligonucleotide Conjugates for Irreversible Cleavage of RNA Sequences.

Staroseletz Y, Gaponova S, Patutina O, Bichenkova E, Amirloo B, Heyman T Molecules. 2021; 26(6).

PMID: 33808835 PMC: 8003597. DOI: 10.3390/molecules26061732.

References
1.
Niittymaki T, Lonnberg H . Artificial ribonucleases. Org Biomol Chem. 2005; 4(1):15-25. DOI: 10.1039/b509022a. View

2.
Serikov R, Petyuk V, Vorobijev Y, Koval V, Fedorova O, Vlassov V . Mechanism of antisense oligonucleotide interaction with natural RNAs. J Biomol Struct Dyn. 2011; 29(1):27-50. DOI: 10.1080/073911011010524987. View

3.
Jones D . The long march of antisense. Nat Rev Drug Discov. 2011; 10(6):401-2. DOI: 10.1038/nrd3474. View

4.
Maier J, Martinez C, Kasavajhala K, Wickstrom L, Hauser K, Simmerling C . ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J Chem Theory Comput. 2015; 11(8):3696-713. PMC: 4821407. DOI: 10.1021/acs.jctc.5b00255. View

5.
Kumar P, Truong L, Baker Y, El-Sagheer A, Brown T . Synthesis, Affinity for Complementary RNA and DNA, and Enzymatic Stability of Triazole-Linked Locked Nucleic Acids (t-LNAs). ACS Omega. 2018; 3(6):6976-6987. PMC: 6028152. DOI: 10.1021/acsomega.8b01086. View